Lingao Ju (He/Him)

Senior Researcher, Zhongnan Hospital of Wuhan University
  • China

USP43 promotes gemcitabine resistance in bladder cancer by stabilizing E2F1 to regulate cholesterol homeostasis

Gemcitabine (GEM) resistance remains a critical barrier in the treatment of bladder cancer (BLCA). Based on the observation that metabolic reprogramming drives chemoresistance, we identified USP43 as a promoter of GEM resistance via an E2F1-driven mechanism that modulates cholesterol metabolism.
Go to the profile of Lingao Ju +4
Lingao Ju and 4 others
Jan 07, 2026